Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Anti-cancer chemotherapy or biologic therapy if administered prior to the first planned dose of study medication (napabucasin or FOLFIRI) within period of time equivalent to the usual cycle length of the regimen. An exception is made for oral fluoropyrimidines (e.g. capecitabine, S-1), where a minimum of 10 days since last dose must be observed prior to the first planned dose of study medication. Standard dose of bevacizumab (5 mg/kg) may be administered prior to FOLFIRI infusion, per Investigator decision, for as long as permanent decision to include or exclude bevacizumab is made prior to patient randomization. Radiotherapy, immunotherapy (including immunotherapy administered for non-malignant diseaseneoplastic treatment purposes), or investigational agents within four weeks of first planned dose of study medication, with the exception of a single dose of radiation up to 8 Gy (equal to 800 RAD) with palliative intent for pain control up to 14 days before randomization.
More than one prior chemotherapy regimen administered in the metastatic setting.
Major surgery within 4 weeks prior to randomization.
Patients with any known brain or leptomeningeal metastases are excluded, even if treated.
Women who are pregnant or breastfeeding. Women should not breastfeed while taking study treatment and for 4 weeks after the last dose of napabucasin or while undergoing treatment with FOLFIRI and for 180 days after the last dose of FOLFIRI.
Gastrointestinal disorder(s) which, in the opinion of the Qualified/Principal Investigator, would significantly impede the absorption of an oral agent (e.g. intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).
Unable or unwilling to swallow napabucasin capsules daily.
Prior treatment with napabucasin.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements.
Known hypersensitivity to 5-fluorouracil/leucovorin
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Known hypersensitivity to irinotecan
Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Patients receiving treatment with St. John's wort or Phenytoin.
Patients who plan to receive yellow fever vaccine during the course of the study treatment.
Abnormal glucuronidation of bilirubin, known Gilbert's syndrome
Patients with QTc interval > 470 milliseconds
For patients to be treated with a regimen containing bevacizumab:
Patients with a history of other malignancies except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for > 3 years.
Any active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy.
Any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol.
Primary purpose
Allocation
Interventional model
Masking
1,253 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal